Cargando…
Novel therapeutic agents in clinical development for systemic lupus erythematosus
Conventional immunosuppressive therapies have radically transformed patient survival in systemic lupus erythematosus (SLE), but their use is associated with considerable toxicity and a substantial proportion of patients remain refractory to treatment. A more comprehensive understanding of the comple...
Autores principales: | Jordan, Natasha, Lutalo, Pamela MK, D’Cruz, David P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667088/ https://www.ncbi.nlm.nih.gov/pubmed/23642011 http://dx.doi.org/10.1186/1741-7015-11-120 |
Ejemplares similares
-
Immunoglobulin light chain allelic inclusion in systemic lupus erythematosus
por: Fraser, Louise D., et al.
Publicado: (2015) -
Editorial: Cutting edge in systemic lupus erythematosus
por: D’Cruz, David P., et al.
Publicado: (2017) -
Intravenous Immunoglobulin in the Therapeutic Armamentarium of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
por: Sakthiswary, Rajalingham, et al.
Publicado: (2014) -
Topical calcineurin inhibitors in systemic lupus erythematosus
por: Lampropoulos, Christos E, et al.
Publicado: (2010) -
Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus
por: Perez-Hernandez, Javier, et al.
Publicado: (2017)